Anti-allergy immunotherapy delivers strong Phase III data – The Pharma Letter (registration)
The Pharma Letter (registration) |
Anti-allergy immunotherapy delivers strong Phase III data
The Pharma Letter (registration) The Belgian biopharmaceutical company, which focuses on immunotherapy products for the treatment of allergies, is developing the drug to combat grass pollen rhinitis. The company reports it is the first ever clinical study to demonstrate the clinical … |
